Melanoma cells are melanocytes gone rogue. Melanocytes are the pigment-producing cells in your skin, and when their DNA accumulates certain critical mutations, they can break free of the body’s normal growth controls and become melanoma. What makes these transformed cells so dangerous is not just uncontrolled growth but a remarkable behavioral repertoire: they can reshape their surrounding tissue, dodge immune detection, build their own blood supply, travel to distant organs, and lie dormant for years before reawakening. Understanding how melanoma cells actually behave, from their origins to the tricks they use to spread, helps explain why this cancer is both one of the most treatable when caught early and one of the most lethal when it is not.
Where Melanoma Cells Come From
Melanocytes originate during embryonic development from a group of cells called the neural crest. These precursor cells migrate throughout the body and eventually settle in the skin, hair follicles, and a few other tissues, where they mature into pigment-producing cells. Once in the skin, melanocytes sit along the bottom layer of the epidermis and extend branching arms into the surrounding cells. Their primary job is making melanin, a pigment packaged into tiny compartments called melanosomes, which get shuttled into neighboring skin cells called keratinocytes. That transferred melanin is what gives skin its color and acts as a natural shield against ultraviolet radiation damage to DNA.1PubMed Central. Skin melanocytes: biology and development
In healthy skin, melanocytes live under tight supervision. Keratinocytes completely surround each melanocyte and regulate its growth, shape, and behavior through direct contact and chemical signaling.2PubMed Central. Dangerous liaisons: Loss of keratinocyte control over melanocytes in melanomagenesis This relationship is so powerful that experiments with co-cultured cells have shown that normal keratinocytes can suppress melanoma-associated surface molecules on melanocytes and keep them in a non-aggressive state.3PubMed Central. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors Melanoma begins when a melanocyte acquires enough genetic damage to slip out from under that control.
How UV Damage Sets the Stage
Ultraviolet radiation is the most important environmental trigger for the mutations that drive melanoma. Both UVB and UVA wavelengths cause distinctive types of DNA damage. UVB radiation produces a characteristic pattern of C-to-T mutations at specific DNA sequences, and genomic sequencing of melanoma tumors has confirmed that these “UVB signature” mutations are widespread across melanoma genomes. UVA radiation contributes its own damage, primarily a different type of DNA lesion at TT sequences, formed through both direct and indirect photochemical processes.4PubMed Central. UVA Radiation, DNA Damage, and Melanoma Not all melanomas are linked to sun exposure, though. Subtypes that arise on the palms, soles, nail beds, or mucosal surfaces follow different mutational paths, which is one reason the disease behaves so differently depending on where it starts.
The Key Genetic Drivers
When researchers sequence melanoma tumors, a handful of genes turn up mutated again and again. In sun-exposed cutaneous melanoma, the most common driver mutation occurs in the BRAF gene, found in roughly 38% of cases in one large Japanese genomic profiling study, followed by NRAS at about 21%, KIT at 10%, and NF1 at 8%.5PubMed. Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data These genes all converge on the same basic effect: they lock the cell’s growth-signaling machinery in the “on” position, pushing the cell to keep dividing when it should stop.
But melanoma is not a single genetic disease. Tumors that lack BRAF and NRAS mutations still find alternative routes to the same outcome. About two-thirds of these “wild-type” melanomas carry activating mutations or gene copy-number changes in other growth-promoting genes.6PubMed. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas Meanwhile, a comprehensive sequencing study across melanoma subtypes found additional mutations scattered across a long tail of less commonly altered genes, creating a landscape where individual tumors each carry their own idiosyncratic collection of genetic damage.7PubMed Central. A landscape of driver mutations in melanoma
Activating growth signals alone are usually not enough to produce a full-blown melanoma. The cell also needs to lose its brakes. One of the most important braking systems involves a gene called PTEN, which normally counteracts growth signals. Loss of PTEN function is associated with the progression of a substantial fraction of melanomas, and while researchers initially thought PTEN’s role was limited to blocking one signaling pathway, recent work suggests it plays a more complex part in keeping melanocytes under control.8PubMed Central. The Roles of PTEN in Melanoma Suppression
Breaking Free From Keratinocyte Control
One of the earliest and most consequential behavioral shifts in melanoma involves the so-called cadherin switch. In healthy skin, melanocytes stick to their keratinocyte neighbors using a surface adhesion molecule called E-cadherin. During melanoma development, cells lose E-cadherin and replace it with a different molecule, N-cadherin. This swap has profound consequences: the melanoma cell loses its physical bond to the cells that had been keeping it in check and gains the ability to interact instead with fibroblasts and blood vessel cells deeper in the skin.9British Journal of Dermatology. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression
The cadherin switch is not just a passive loss. It actively reshapes the melanoma cell’s behavior, transforming it from a rounded, well-attached cell into an elongated, mobile one with a more aggressive character. In laboratory studies, drugs that reverse this switch can push aggressive melanoma cells back toward a more normal shape and reduce their ability to spread.10PubMed Central. Protein kinase C inhibitor Gö6976 but not Gö6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1 Researchers are still working to understand exactly how the switch gets initiated and maintained, though new evidence points to signaling from the surrounding tissue cells as a key regulator.11Oncogene. YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression
Growth Phases and Early Invasion
Clinicians have long described melanoma progression in two main phases. In the radial growth phase, the tumor spreads horizontally within the upper skin layers, expanding outward like an ink stain on paper. During this phase the cancer is thin, confined, and highly curable if removed. Mathematical modeling of this process has shown that the loss of adhesion to both the basement membrane below and the keratinocytes around the melanocyte are the fundamental mechanical triggers that allow the tumor to begin spreading, even before it starts growing downward.12PubMed Central. The radial growth phase of malignant melanoma: multi-phase modelling, numerical simulations and linear stability analysis
The transition from radial to vertical growth marks a critical turning point. In the vertical growth phase, melanoma cells begin pushing downward into deeper layers of the skin, toward blood vessels and lymphatic channels. This is when the tumor acquires metastatic potential, the ability to seed itself in distant organs. The deeper a melanoma grows, the worse the prognosis, which is why early detection and removal during the radial phase is so effective.
How Melanoma Cells Spread to Distant Organs
Melanoma is notorious for its ability to metastasize to almost any organ, but it shows preferences. Common destinations include the lungs, liver, brain, bone, and distant skin sites. How melanoma cells home to specific organs is a complicated question. Research suggests it involves a mix of blood-flow patterns, chemical signals from distant tissues, and the cell’s own molecular toolkit, though the mechanisms are complicated by the observation that melanocytes can sometimes disseminate before they are fully malignant.13PubMed Central. Decoding melanoma metastasis
The liver provides a vivid example of how hostile and selective the metastatic process really is. When melanoma cells arrive in the liver’s tiny blood vessels, the local environment actively tries to kill them. Chemicals produced by the blood vessel lining and by immune cells destroy the majority of melanoma cells that reach the organ. The survivors can then escape the blood vessel either by squeezing through natural gaps in the vessel wall or by growing inside the vessel until it ruptures, allowing the cells to establish a foothold in the surrounding tissue.14PubMed. Melanoma in the liver: Oxidative stress and the mechanisms of metastatic cell survival This inefficiency is true of metastasis generally: most cancer cells that enter the bloodstream die. The ones that survive are the dangerous exceptions.
Remodeling the Neighborhood
Melanoma cells do not simply invade passively. They actively reshape the tissue around them to create a more hospitable environment. One of the most important ways they do this is by converting normal fibroblasts, the structural cells of connective tissue, into cancer-associated fibroblasts. These co-opted cells then produce growth factors, remodel the tissue matrix, and even help prepare distant organs for the arrival of metastatic cells by contributing to the formation of a “pre-metastatic niche.”15PubMed Central. The Role of Fibroblasts in Melanoma Development: From Tumor Microenvironment Remodeling to Pre-Metastatic Niche Formation
This distant organ preparation involves another striking behavior. Melanoma cells release tiny membrane-bound packets called exosomes into the bloodstream. In mouse models, exosomes from aggressive melanoma cells were shown to increase blood vessel permeability in the lungs and alter gene expression in lung tissue, creating conditions favorable for incoming tumor cells. Mice pre-treated with melanoma exosomes before tumor implantation developed significantly more lung metastases than controls.16Nature Reviews Cancer. Tumour-derived exosomes promote metastasis In other words, melanoma can begin preparing the ground at a distant site before a single tumor cell even arrives there.
Building Their Own Blood Supply
All tumors need blood to grow, and melanoma stimulates the formation of new blood vessels through a process called angiogenesis. But aggressive melanoma cells have an additional trick: vasculogenic mimicry. These cells can form their own channel-like structures that look and function like blood vessels, without any help from actual blood vessel cells. The channels, first identified in aggressive uveal melanoma, appear in both primary and metastatic tumors and are associated with worse outcomes.17PubMed Central. Vasculogenic mimicry and tumor angiogenesis
This mimicry is especially important under low-oxygen conditions. When conventional blood vessel growth is insufficient, melanoma cells adapt by forming these vascular-like structures, enabling the tumor to keep growing and fueling further metastasis. The presence of vasculogenic mimicry in a melanoma tumor is linked to greater spread and resistance to treatments that target normal blood vessel formation.18PubMed Central. Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance
Hiding From the Immune System
Melanoma has long been considered one of the most “immunogenic” cancers, meaning the immune system often recognizes it. This is precisely why immunotherapy works well for many melanoma patients. Yet melanoma cells are also adept at evading immune destruction. One key escape mechanism involves downregulating the molecules on the cell surface that flag it for immune recognition. Analysis of melanomas resistant to checkpoint-inhibitor immunotherapy has confirmed that reduced expression of these surface markers is a hallmark of treatment resistance. The resistant cells tend to shift into a de-differentiated state and are surrounded by cancer-associated fibroblasts, and a signaling molecule called TGF-beta appears to drive both the de-differentiation and the loss of immune visibility.19Nature Communications. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition
The immune signaling pathway that melanoma cells exploit runs through a molecule called JAK1, which is required for interferon-gamma to trigger the expression of both the surface recognition markers and the PD-L1 checkpoint molecule. When melanoma cells lose JAK1 function, they become invisible to one of the immune system’s most important anti-tumor signals.20PubMed Central. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 This dual ability to hide and to resist treatment makes the immune evasion machinery of melanoma cells a central focus of current research.
How Melanoma Subtypes Differ
Not all melanomas are created equal. The four major subtypes, cutaneous (sun-exposed skin), acral (palms, soles, nail beds), mucosal (internal body surfaces), and uveal (eye), each have distinct genetic profiles that affect how the cells behave and which treatments they respond to.
Acral melanoma, which is the most common subtype in people with darker skin, carries more structural DNA changes and gene amplifications than cutaneous melanoma. KIT mutations are more prominent, and certain gene amplifications are more common. Mucosal melanoma has its own molecular signature, including mutations found almost exclusively in that subtype. Uveal melanoma is the most genetically distinct: roughly 87% of cases carry driver mutations in either GNAQ or GNA11, genes that are almost never mutated in skin melanomas.5PubMed. Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data Researchers have also found that some acral melanomas carrying a particular BRAF mutation but few structural DNA changes may actually be more closely related to cutaneous melanomas than to other acral tumors, suggesting the boundaries between subtypes are blurrier than once thought.21PubMed Central. Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
These genetic differences have real clinical consequences. Drugs that target BRAF mutations work well in cutaneous melanomas harboring those mutations but are useless against uveal melanoma, which is driven by entirely different genes. KIT-targeted therapies are more relevant for acral and mucosal disease. The shift toward molecular profiling of each patient’s tumor reflects the recognition that “melanoma” is really a family of related but distinct diseases.
Why Targeted Therapies Stop Working
Drugs that target mutated BRAF were a breakthrough in melanoma treatment, but resistance is a persistent problem. About a fifth of patients never respond at all due to intrinsic resistance, and most who do respond eventually relapse, often within months.22PubMed Central. Resistant mechanisms to BRAF inhibitors in melanoma The cells find workarounds: reactivating the same growth-signaling pathway through a different entry point, switching on alternative growth receptors, or leaning on interactions with the surrounding tumor microenvironment to keep growing.23PubMed Central. BRAF inhibitors: resistance and the promise of combination treatments for melanoma
This adaptability is one of the defining features of melanoma cell behavior. The same plasticity that allows a neural crest cell to migrate across the embryo and differentiate into a melanocyte seems to be repurposed by melanoma cells to switch identities and escape treatment pressure. Combining targeted drugs with immunotherapy has become a major strategy to try to stay ahead of the cancer’s ability to evolve.
Metabolic Shifts in Melanoma Cells
As melanoma progresses, its cells undergo a metabolic reorganization. Healthy cells primarily burn fuel using oxygen-dependent processes in their mitochondria. Melanoma cells increasingly shift toward a less efficient but faster mode of energy production that relies on breaking down glucose in the cell’s main compartment, even when oxygen is available. This switch lets the cells meet the intense demand for both energy and raw building materials that rapid growth requires. Well-known melanoma driver genes, including BRAF and PTEN, are directly involved in regulating this metabolic shift, meaning the same mutations that drive growth also rewire the cell’s energy economy.24Trends in Molecular Medicine. Metabolic rewiring of melanoma and its therapeutic implications
This metabolic rewiring creates potential therapeutic opportunities, because drugs that interfere with the altered energy pathways could starve melanoma cells. The challenge, however, is that not all melanoma cells within a single tumor use the same metabolic strategy. Variation in the genetic driver profile and mitochondrial function across different regions of a tumor creates a patchwork of metabolic states, meaning a drug that hits one population may leave another untouched.
Dormancy and Late Relapse
One of the most unsettling features of melanoma is its capacity for dormancy. Even after successful treatment that eliminates all visible disease, individual melanoma cells can survive in specialized niches throughout the body, entering a state of suspended animation where they stop dividing and essentially go silent. These dormant cells do not form tumors, do not cause symptoms, and do not respond well to most therapies because those therapies are designed to target actively dividing cells.25PubMed Central. Dormancy of cutaneous melanoma
Dormancy explains why melanoma can recur years or even decades after the original tumor was removed. What triggers a dormant cell to reawaken and begin proliferating again is still poorly understood and remains one of the most active areas of melanoma research. Changes in immune surveillance, inflammation, or signals from the tissue environment are all suspected triggers, but there is no reliable way to predict when or whether a dormant cell will wake up.
Melanoma Stem-Like Cells
Within a melanoma tumor, not all cells are equally dangerous. A subset of cells with stem-like properties appears to be especially capable of self-renewal, differentiation into other cell types, and initiating new tumors. These cells express a surface marker called ABCB5, and populations enriched for this marker have been shown to have the capacity to regenerate entire tumors in experimental settings, leading researchers to identify them as melanoma-initiating cells.26BMB Reports. Cancer stem cell surface markers on normal stem cells ABCB5 also functions as a drug-efflux pump, meaning these cells can actively expel chemotherapy drugs, which may partly explain why they survive treatments that kill the bulk of the tumor. The existence of these stem-like populations adds another layer of difficulty to achieving lasting cures, because even a treatment that eliminates 99% of a tumor may leave behind the cells most capable of rebuilding it.